Is Cardiff Oncology Stock a Good Investment?
Cardiff Oncology Investment Advice | CRDF |
- Examine Cardiff Oncology's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Cardiff Oncology's leadership team and their track record. Good management can help Cardiff Oncology navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Cardiff Oncology's business and its evolving consumer preferences.
- Compare Cardiff Oncology's performance and market position to its competitors. Analyze how Cardiff Oncology is positioned in terms of product offerings, innovation, and market share.
- Check if Cardiff Oncology pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Cardiff Oncology's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Cardiff Oncology stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Cardiff Oncology is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Modest | Details | |
Volatility | Very risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Cardiff Oncology Stock
Researching Cardiff Oncology's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 26.0% of the company shares are held by institutions such as insurance companies. The book value of Cardiff Oncology was currently reported as 1.01. The company recorded a loss per share of 0.95. Cardiff Oncology last dividend was issued on the 20th of February 2019. The entity had 1:6 split on the 20th of February 2019.
To determine if Cardiff Oncology is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Cardiff Oncology's research are outlined below:
| Cardiff Oncology had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 488 K. Net Loss for the year was (41.44 M) with loss before overhead, payroll, taxes, and interest of (26.72 M). | |
| Cardiff Oncology currently holds about 122.01 M in cash with (30.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.82, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Cardiff Oncology has a frail financial position based on the latest SEC disclosures |
Cardiff Oncology uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Cardiff Oncology. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cardiff Oncology's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Cardiff Oncology's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 133.46 M.Basic technical analysis of Cardiff Stock
As of the 3rd of December, Cardiff Oncology shows the Downside Deviation of 7.41, mean deviation of 3.93, and Risk Adjusted Performance of 0.0722. Cardiff Oncology technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Cardiff Oncology value at risk, and the relationship between the jensen alpha and semi variance to decide if Cardiff Oncology is priced correctly, providing market reflects its regular price of 2.66 per share. Please also double-check Cardiff Oncology total risk alpha, which is currently at (0.39) to validate the company can sustain itself at a future point.Cardiff Oncology's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cardiff Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cardiff Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cardiff Oncology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cardiff Oncology's Outstanding Corporate Bonds
Cardiff Oncology issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cardiff Oncology uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cardiff bonds can be classified according to their maturity, which is the date when Cardiff Oncology has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| CARDINAL HEALTH INC Corp BondUS14149YAW84 | View | |
| CARDINAL HEALTH INC Corp BondUS14149YBJ64 | View | |
| CARDINAL HEALTH INC Corp BondUS14149YBE77 | View | |
| CARDINAL HEALTH INC Corp BondUS14149YBD94 | View | |
| CARDINAL HEALTH INC Corp BondUS14149YBA55 | View |
Understand Cardiff Oncology's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Cardiff Oncology's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0722 | |||
| Market Risk Adjusted Performance | 0.5109 | |||
| Mean Deviation | 3.93 | |||
| Semi Deviation | 6.01 | |||
| Downside Deviation | 7.41 | |||
| Coefficient Of Variation | 1202.37 | |||
| Standard Deviation | 5.79 | |||
| Variance | 33.49 | |||
| Information Ratio | 0.0617 | |||
| Jensen Alpha | 0.3638 | |||
| Total Risk Alpha | (0.39) | |||
| Sortino Ratio | 0.0482 | |||
| Treynor Ratio | 0.5009 | |||
| Maximum Drawdown | 41.21 | |||
| Value At Risk | (8.03) | |||
| Potential Upside | 9.48 | |||
| Downside Variance | 54.89 | |||
| Semi Variance | 36.11 | |||
| Expected Short fall | (4.11) | |||
| Skewness | (0.96) | |||
| Kurtosis | 5.47 |
| Risk Adjusted Performance | 0.0722 | |||
| Market Risk Adjusted Performance | 0.5109 | |||
| Mean Deviation | 3.93 | |||
| Semi Deviation | 6.01 | |||
| Downside Deviation | 7.41 | |||
| Coefficient Of Variation | 1202.37 | |||
| Standard Deviation | 5.79 | |||
| Variance | 33.49 | |||
| Information Ratio | 0.0617 | |||
| Jensen Alpha | 0.3638 | |||
| Total Risk Alpha | (0.39) | |||
| Sortino Ratio | 0.0482 | |||
| Treynor Ratio | 0.5009 | |||
| Maximum Drawdown | 41.21 | |||
| Value At Risk | (8.03) | |||
| Potential Upside | 9.48 | |||
| Downside Variance | 54.89 | |||
| Semi Variance | 36.11 | |||
| Expected Short fall | (4.11) | |||
| Skewness | (0.96) | |||
| Kurtosis | 5.47 |
Consider Cardiff Oncology's intraday indicators
Cardiff Oncology intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Cardiff Oncology stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Cardiff Oncology time-series forecasting models is one of many Cardiff Oncology's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cardiff Oncology's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Cardiff Stock media impact
Far too much social signal, news, headlines, and media speculation about Cardiff Oncology that are available to investors today. That information is available publicly through Cardiff media outlets and privately through word of mouth or via Cardiff internal channels. However, regardless of the origin, that massive amount of Cardiff data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Cardiff Oncology news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Cardiff Oncology relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Cardiff Oncology's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Cardiff Oncology alpha.
Cardiff Oncology Corporate Management
| James Levine | Chief Officer | Profile | |
| Mark Erlander | CEO Director | Profile | |
| Vicki Kelemen | Chief Officer | Profile | |
| Tod Smeal | Chief Officer | Profile | |
| Brigitte Lindsay | Senior Finance | Profile | |
| MD FACP | Chief Officer | Profile | |
| Charles RPh | Senior Affairs | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiff Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For more detail on how to invest in Cardiff Stock please use our How to Invest in Cardiff Oncology guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiff Oncology. If investors know Cardiff will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiff Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cardiff Oncology is measured differently than its book value, which is the value of Cardiff that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiff Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cardiff Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiff Oncology's market value can be influenced by many factors that don't directly affect Cardiff Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Cardiff Oncology's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Cardiff Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiff Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.